HCL-FOUNDATION
16.2.2021 11:37:15 CET | Business Wire | Press release
HCL Foundation, the corporate social responsibility arm of HCL Technologies Ltd., today announced the winners of the sixth round of the HCL Grant, a flagship program dedicated to strengthening India’s “fifth estate” of NGOs working towards nation building.
The three NGOs, one each in the development areas of environment, health, and education, will each receive a grant of INR 5 crore ($685,000) for a three to five-year project. In addition, two finalists in each category will receive a one-year grant of INR 25 lakhs ($34,000), making a total grant of INR 16.5 crore.
HCL Foundation, which this year celebrates a decade of building strong and robust communities, is committed to contributing to the nation’s growth curve. Under its HCL Grant program, the Foundation has so far committed a more than INR 60 crore ($8.26 Million), excluding this year’s grants. Recognized as one of the most sought-after validations amongst NGO ecosystems in India, the HCL Grant has in the past five years reached over 733,000 beneficiaries. The Grant aims to touch the lives of at least 1.72 million people in 8,598 villages in 70 districts across 18 states and two union territories of India.
The winning NGOs of HCL Grant 2021 were:
- Saahas (Environment)
- India Health Action Trust (Health)
- Child Rights and You (Education)
The NGOs were chosen after an 8-month review of thousands of applications by an eminent jury, monitored and audited by Grant Thornton, the governance partner of HCL Grant. The jury consisted of: Ms. Robin Abrams, Director, HCL Technologies, and Chairperson of the jury; Mr. Suresh Narayanan, Chairman and Managing Director, Nestle India Limited; Mr. B. S. Baswan, former Director, Indian Institute of Public Administration, and former Secretary, Human Resource Development ministry; Ms. Pallavi Shroff, Managing Partner, Shardul Amarchand Mangaldas & Co. law firm; Dr. Richard Lariviere, President Emeritus, Field Museum (Chicago), and former President, University of Oregon; and Mr. Shiv Nadar, Founder of HCL, Chief Strategy Officer of HCL Technologies, and Founder and Chairman of the Shiv Nadar Foundation.
“The past year was a unique year of resilience and transformation that taught us how to transcend barriers and keep going even in the face of adversity,” said Ms. Abrams. “Despite the pandemic, the robustness demonstrated by our NGO partners, experts, jury members and the entire team is commendable. The passion and zeal of our NGO partners to bring in scalable and replicable solutions have created systemic shifts across geographies, lending velocity to the sustainable development agenda. The winners and finalists of this year’s Grant also have significant stories to tell, with visible on-the-ground impact. My best wishes to these NGOs, who are addressing some of the most pressing issues in the key development categories of environment, health, and education in the most remote corners of the country.”
Ms. Nidhi Pundhir, Director, HCL Foundation, said: “The year 2020 has been both special and unusual. Special, in that the Foundation is completing ten years of facilitating high-impact, sustainable socio-economic development in rural India. Unusual, in that the NGOs we support had to deal with unprecedented challenges posed by the pandemic and various natural disasters, while initiating and implementing their developmental projects. What is inspiring about these NGOs is that they are treating COVID-19 as the ‘new normal’ and are continuing with their path-breaking projects without a pause, creating a much-needed last-mile support framework.”
On the occasion of the grant awards, the HCL Foundation released “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education,” a compendium featuring the top 30 NGOs selected in the sub-jury round, as well as the previous year’s winning NGOs.
For more information please visit www.hclfoundation.org/hcl-grant
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005593/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
